Search company, investor...
Alimera Sciences company logo

Alimera Sciences

alimerasciences.com

Founded Year

2003

Stage

Corporate Minority - P2P | IPO

Total Raised

$95.11M

Market Cap

0.03B

Stock Price

3.54

About Alimera Sciences

Alimera Sciences is a specialty pharmaceutical company focused on the ophthalmic industry. The Company was formed by the former management team of Novartis Ophthalmics.

Headquarters Location

6120 Windward Parkway Suite 290

Alpharetta, Georgia, 30005,

United States

678-990-5740

Missing: Alimera Sciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Alimera Sciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Alimera Sciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Alimera Sciences is included in 2 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

D

Diabetes

1,898 items

Alimera Sciences Patents

Alimera Sciences has filed 1 patent.

The 3 most popular patent topics include:

  • Beta blockers
  • Blindness
  • Diseases of the eye and adnexa
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/2/2019

8/2/2022

Diseases of the eye and adnexa, Disorders of choroid and retina, Blindness, Ophthalmology, Beta blockers

Grant

Application Date

5/2/2019

Grant Date

8/2/2022

Title

Related Topics

Diseases of the eye and adnexa, Disorders of choroid and retina, Blindness, Ophthalmology, Beta blockers

Status

Grant

Latest Alimera Sciences News

Alimera Highlights Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN® Administration

Nov 29, 2022

Alpharetta, Georgia, UNITED STATES ATLANTA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announces findings from a recent meeting where data demonstrated a high level of agreement among retina specialists on the role of inflammation in the pathophysiology of diabetic retinopathy (DR) and diabetic macular edema (DME), injection burden and patient adherence, and efficacy and safety of ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant. The company also announced analysis of data from the 36-month PALADIN study that found 0.19 mg Fluocinolone Acetonide (FAc) provides long-term reduction of retinal thickness variability (RTV), which is correlated to improved visual outcomes and better disease control. These results were made available at the annual scientific meeting of The Retina Society held in Pasadena, CA from November 2-5, 2022. “We are excited to see a consensus in the retina community on the increasing understanding of the role of inflammation in diabetic eye disease, and the efficacy and safety of ILUVIEN in treating DME,” said Rick Eiswirth, President and CEO of Alimera. “We are also pleased to see the continuing impact of the PALADIN Study of ILUVIEN, including another abstract presented at the recent annual meeting of The Retina Society. The PALADIN Study data presented demonstrates the correlation between reduced RTV and better visual acuity, and the value of ILUVIEN’s CONTINUOUS MICRODOSING™ in controlling RTV.” Anton Kolomeyer, MD, PhD authored a poster titled, “Fluocinolone acetonide and DME – An Expert Consensus.” To understand the level of agreement among retinal physicians in the US on the safety and efficacy of FAc in DME treatment, as well as the role of inflammation in the pathophysiology of DR and DME, researchers disseminated a survey to retina specialists. The full survey was completed by 56 physicians. The modified Likert grading scale was used to evaluate consensus. Key Abstract Findings: A consensus was reached for seven of ten proposed statements. These included those related to: Chronic low-grade inflammation and the associated inflammatory cytokines (VEGF, IL-6, etc.) are key drivers of DR/DME pathogenesis. Steroids have broad, non-specific anti-inflammatory properties, including the downregulation of VEGF production. Chronic low-grade inflammation, a result of poor glycemic control over time, can lead to neurodegenerative changes in the diabetic retina. High injection burden tied to the use of short acting therapies may lead to patient fatigue and lack of adherence, thereby limiting treatment efficacy. High injection burden and poor patient adherence can lead to increased amplitude and frequency of retinal fluctuations, which may lead to irreversible vision loss in some patients. The 0.19 mg fluocinolone acetonide implant can minimize retinal thickness fluctuations and reduce treatment burden through continuous and consistent treatment over 36 months. IOP elevation associated with the 0.19 mg fluocinolone acetonide implant is manageable in the majority of cases with topical IOP lowering therapy. Although below the consensus threshold, physicians were in high agreement that “the 0.19 mg fluocinolone acetonide implant may represent a viable treatment option to establish early baseline control of the underlying low-grade, chronic inflammatory disease in patients with DR/DME,” and 93% of clinicians identified at least one clinical situation in which they would consider the use of steroids as baseline therapy. Veeral Sheth, MD, MBA presented the abstract titled, “The 0.19 mg Fluocinolone Acetonide (FAc) Implant Reduces the Recurrence of Edema by Providing Long-Term Control of Retinal Thickness Variability in Patients with DME: The 3-Year PALADIN Study.” According to the abstract, data from the PALADIN phase IV, real world observational study support that the FAc implant significantly reduces RTV through reduction of the recurrence of edema. The authors point out that no new safety signals were identified during the Study, and they highlight the FAc implant as the only long-term therapy providing consistent control of RTV in patients with DME. Key Abstract Findings:

Alimera Sciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Alimera Sciences Rank

Alimera Sciences Frequently Asked Questions (FAQ)

  • When was Alimera Sciences founded?

    Alimera Sciences was founded in 2003.

  • Where is Alimera Sciences's headquarters?

    Alimera Sciences's headquarters is located at 6120 Windward Parkway, Alpharetta.

  • What is Alimera Sciences's latest funding round?

    Alimera Sciences's latest funding round is Corporate Minority - P2P.

  • How much did Alimera Sciences raise?

    Alimera Sciences raised a total of $95.11M.

  • Who are the investors of Alimera Sciences?

    Investors of Alimera Sciences include Ocumension Therapeutics, Paycheck Protection Program, Scale Venture Partners, InterSouth Partners, Domain Associates and 6 more.

  • Who are Alimera Sciences's competitors?

    Competitors of Alimera Sciences include Ology Bioservices, Aegerion Pharmaceuticals, OcuCure Therapeutics, Sequel Pharmaceuticals, Ikaria and 10 more.

Compare Alimera Sciences to Competitors

S
Sirion Holdings

Sirion Holdings is a specialty pharmaceutical company focused on ophthamology drugs

QOL Medical Logo
QOL Medical

QOL Medical is a specialty pharmaceutical company focused on the gastrointestinal market.

I
IVREA Pharmaceuticals

IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.

U
Urigen Pharmacueticals

Urigen specializes in the design and commercialization of innovative products for patients with urological ailments. The company develops products for amelioration of Painful Bladder Syndrome (PBS), Urethritis, Nocturia and Over Active Bladder (OAB).

M
Meditrina Pharmaceuticals

Meditrina Pharmaceuticals, Inc. is a clinical-stage, specialty pharmaceutical company focused on developing and commercializing therapies that treat women's reproductive system disorders, with an initial focus on gynecologic and aromatase-mediated conditions with serious unmet medical needs.

A
Axcan

Axcan is a specialty pharmaceutical company focused on the development and commercialization of drugs for diseases involving the digestive system.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.